Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $146.1952W HIGH $333.30
Volume
252.74 K
Value Traded
279.86 M
Short % Float
6.1%
Days to Cover
2.7
+4.7%Week
+12.21%1 Month
+42.7%3 Month
+70.99%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
14.95 B
EPS (TTM)
-5.00
P/E Ratio
-
Ent. Value
14.66 B
Total Shares
47.71 M
Float Shares
47.20 M
Insiders
1.12%
Institutions
123.99%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CRL Catalyst Timeline
Dated clinical, regulatory and corporate events for Charles River Laboratories International, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Charles River Laboratories International, Inc.
78Total events
5Upcoming
19Tier-1 (high impact)
2016 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseCorporate
Charles River and Magellan Stem Cells announce collaboration for stem cell therapy development and testing
▲Partnership / LicenseZelestrocelCorporate
Charles River and Magellan Stem Cells announce collaboration to support Zelestrocel development
osteoarthritissource ↗
▲Partnership / LicenseCorporate
Charles River and Autolomous launch Apollo Orchestrate built on autoloMATE LES
▲Partnership / LicenseCorporate
Charles River and Medigen collaborate on virus seed bank characterization for next-generation multivalent enterovirus vaccine
◆Management ChangeCorporate
Matthew L. Daniel to step down as General Counsel after July 1, 2026
▲Manufacturing MilestoneCMC / Inspection
Automated manufacturing suite became fully operational
▲PublicationPresentation
Retrospective analysis of VCGs published in Regulatory Toxicology and Pharmacology
▲Other Regulator MilestoneEx-US Regulatory
EMA draft qualification for VCGs in DRF non-GLP rat studies
▲Partnership / LicenseCorporate
Charles River enters CDMO collaboration with Gazi University for gene therapy manufacturing
Hyperphosphatemic tumoral calcinosis (HTC)source ↗
◆Management ChangeCorporate
Names Dr. Namandjé Bumpus as Chief Scientific and Innovation Officer
●Quarterly UpdateCorporate
Charles River Laboratories reports Q3 2023 revenue of $1.03 billion, GAAP EPS $1.69, non-GAAP EPS $2.72
●Quarterly UpdateCorporate
Updated 2023 guidance: revenue growth 2.5%-4.5%, non-GAAP EPS $10.30-$10.90
●Quarterly UpdateCorporate
Updated 2023 guidance: organic revenue growth 5.0%-7.5%, non-GAAP EPS $9.90-$10.90
◆Oral PresentationPresentation
Virtual presentation at Credit Suisse 30th Annual Healthcare Conference
▲Quarterly UpdateCorporate
Third-quarter 2021 revenue of $895.9 million, GAAP EPS $2.01, non-GAAP EPS $2.70
◆Oral PresentationPresentation
Bank of America 2021 Health Care Conference virtual presentation
▲Quarterly UpdateCorporate
Charles River Laboratories reports Q4 2020 revenue of $791.0M and full-year 2020 revenue of $2.92B
▲Quarterly UpdateCorporate
Provides 2021 guidance: reported revenue growth 12-14% (ex-Cognate), non-GAAP EPS $9.00-$9.25
◆Oral PresentationPresentation
Virtual presentation at Bank of America 2020 Health Care Conference
Past FDA Catalysts and PDUFA Decisions
How CRL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every CRL program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Parisotto Shannon MOfficer (CEVP, Disc & Safety Assessment) | Option | 981 5,788 held | $208.44 | 10/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CRL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0.5 % (-16.7 %) | 31.75 M | 140.00 K | 40% ( 40.00 K) |
CRL Institutional Ownership Trends
CRL Short Interest
Shares sold short, counted twice a month.
6.1%
Short % of Float
of tradable shares sold short
2.9M
Shares Sold Short
+29.1% vs prior count
2.7 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.1M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CRL ranks across every disease it competes in
Competitive Position is a premium feature
See how CRL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCRL News
-CRL
Oct 13, 2026Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development
Charles River Laboratories and Magellan Stem Cells have announced a collaboration to advance stem cell therapies, particularly focusing on the off-the-shelf therapy Zelestrocel for osteoarthritis. The partnership will utilize Charles River's expertise in biologics quality control and NGS services to support the development and commercialization of these therapies. Magellan is preparing to launch its pivotal Phase III program after successful Phase I/II trials.
Read more →-CRL
Oct 9, 2026Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call
Charles River Laboratories International, Inc. will announce its third-quarter 2026 financial results on November 4, 2026, before market opening. A conference call to discuss these results is scheduled for the same day at 9:00 a.m. ET. Investors can access a live webcast and a replay through the company's Investor Relations website.
Read more →-CRL
Oct 6, 2026Charles River and Autolomous Partner to Transform Laboratory Execution Systems
Charles River Laboratories and Autolomous have announced the launch of Apollo Orchestrate™, a new feature within the Apollo® platform. This capability aims to digitize and connect laboratory execution systems, showcasing Charles River's ongoing commitment to modernizing laboratory workflows. The collaboration reflects a strategic move towards enhanced efficiency in drug discovery processes.
Read more →-CRL
Sep 24, 2026▲ +6.2%on this news
Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day
Charles River Laboratories presented its refreshed strategic vision, 'Pathway to Purpose', during its 2026 Investor Day. The strategy aims to modernize operations, enhance its scientific portfolio, and improve client experiences. The company reaffirmed its 2026 financial guidance and set long-term targets through 2030, anticipating substantial growth in revenue and earnings.
Read more →-CRL
Sep 17, 2026Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
Charles River Laboratories has launched rapid cell banking programs aimed at reducing release timelines for biopharmaceutical and advanced therapy developers. This initiative combines rapid cell bank and release packages with advanced characterization techniques, such as Next-Generation Sequencing (NGS). The goal is to help developers reach critical milestones more quickly and deliver innovative treatments to patients sooner.
Read more →-CRL
Sep 11, 2026Charles River Laboratories to Present at Morgan Stanley and Baird Conferences
Charles River Laboratories International, Inc. announced its participation in two upcoming investor conferences: the Morgan Stanley 24th Annual Global Healthcare Conference and the Baird 2026 Global Healthcare Conference. Management will provide insights into the company's strategic focus and recent business developments. Live webcasts of the presentations will be available, along with replays for two weeks post-event.
Read more →-CRL
Sep 8, 2026Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite
Charles River Laboratories has launched its Endosafe® Cartridge Technology Automated Manufacturing Suite, enhancing the production of bacterial endotoxin testing cartridges. This new suite aims to improve in-process inspection, digital traceability, and overall manufacturing controls. The suite is expected to reach full operational capacity by Q3 2026, marking a significant investment in advanced manufacturing technology.
Read more →-CRL
Aug 20, 2026Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing
Charles River Laboratories is collaborating with Medigen Vaccine Biologics Corp. to advance the development of a next-generation multivalent enterovirus vaccine. This partnership will utilize Charles River's advanced analytical platforms, including Next-Generation Sequencing, to aid in the characterization and validation of the virus seed bank. The collaboration aims to enhance the Chemistry, Manufacturing, and Controls activities for the vaccine.
Read more →-CRL
Aug 5, 2026▲ +11.4%on this news
Charles River Laboratories Announces Second-Quarter 2026 Results
Charles River Laboratories reported its Q2 2026 results, revealing a revenue of $1.00 billion and a GAAP loss per share of $(0.03). Despite a revenue decrease of 2.7% from the previous year, the company increased its guidance for 2026 due to improving demand trends. The report highlighted successful stock repurchases and strategic collaborations to enhance drug discovery efforts.
Read more →-CRL
Jul 15, 2026Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call
Charles River Laboratories International, Inc. will announce its second-quarter 2026 financial results on August 5, 2026. A conference call is set for the same day at 9:00 a.m. ET to discuss these results. Investors can access a live webcast and a replay through the company's Investor Relations website.
Read more →-CRL
Jul 13, 2026Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches
Charles River Laboratories has partnered with Arovella Therapeutics to provide GMP Next Generation Sequencing services. This collaboration aims to support Arovella in developing an Invariant Natural Killer T cell therapy platform for cancer treatment. The partnership is expected to accelerate progress towards innovative cancer treatment approaches.
Read more →-CRL
Jun 18, 2026Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise
Charles River Laboratories has partnered with Eli Lilly's TuneLab to enhance their AI/ML platform by leveraging Charles River's expertise in nonclinical testing. This collaboration aims to optimize the integration of artificial intelligence and machine learning in drug development processes. The partnership reflects a growing trend in the biopharma industry to utilize advanced technologies for improving research outcomes.
Read more →-CRL
Jun 1, 2026Charles River Laboratories to Present at William Blair and Jefferies Conferences
Charles River Laboratories announced its participation in two upcoming conferences: the William Blair 46th Annual Growth Stock Conference on June 2 and the Jefferies Global Healthcare Conference on June 3. Management will discuss the company's strategic focus and recent business developments. Live webcasts of the presentations will be available on their website.
Read more →-CRL
May 11, 2026▼ -5.2%on this news
Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow
Charles River is enhancing its digital pathology services through the implementation of an AI-powered end-to-end workflow. This advancement aims to streamline processes and improve efficiency in pathology diagnostics. The initiative reflects a growing trend in the biopharma industry towards integrating artificial intelligence in laboratory settings.
Read more →-CRL
Apr 21, 2026Charles River Highlights Effectiveness of VCGs in Toxicology
Charles River Laboratories has released a retrospective analysis demonstrating the effectiveness of virtual control groups (VCGs) in toxicology studies. The analysis showed that VCGs can replace traditional animal models without compromising scientific integrity, achieving 100% concordance in key safety assessments. The initiative aims to enhance study efficiency and reduce animal use in research, supported by ongoing collaborations with regulatory agencies.
Read more →-CRL
Apr 17, 2026Charles River Laboratories Schedules First-Quarter 2026 Earnings Release and Conference Call
Charles River Laboratories International, Inc. will release its first-quarter 2026 financial results on May 7th, prior to market opening. A conference call is set for the same day at 8:30 a.m. ET to discuss these results. Investors can access a live webcast and a replay through the company's Investor Relations website.
Read more →-CRL
Mar 2, 2026Charles River Laboratories to Present at TD Cowen and Barclays Conferences
Charles River Laboratories announced its participation in two upcoming investor conferences. Management will present an overview of the company's strategic focus, business developments, and recent trends. Live webcasts of the presentations will be available, with replays accessible for at least two weeks. This engagement highlights the company's commitment to transparency and investor relations.
Read more →-CRL
Feb 18, 2026Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance
Charles River Laboratories reported a fourth-quarter revenue of $994.2 million for 2025, reflecting a slight decrease from the previous year. The company experienced a GAAP loss per share of $(5.62) due to significant non-cash impairments. Despite these challenges, Charles River expressed cautious optimism for 2026, anticipating a return to organic revenue growth driven by improved demand trends and strategic initiatives.
Read more →-CRL
Feb 18, 2026Charles River Laboratories Announces Executive Appointments
Charles River Laboratories has announced the appointment of Glenn G. Coleman as Chief Financial Officer and Kerry Dailey as Chief Legal Officer. These appointments are part of a strategic effort to strengthen the leadership team and enhance operational efficiency. Both executives bring extensive experience in their respective fields, aiming to drive growth and shareholder value.
Read more →-CRL
Jan 22, 2026Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call
Charles River Laboratories will announce its fourth-quarter and full-year 2025 financial results on February 18th, along with guidance for 2026. A conference call is set for the same day at 8:30 a.m. ET, allowing investors to engage directly with the company's leadership. This event reflects the company's commitment to transparency and investor relations.
Read more →About Charles River Laboratories International, Inc.
Headquarters251 BALLARDVALE ST, WILMINGTON, MA, 01887
BIOPHARMAWATCH ELITE PLUS
Trade the next CRL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime